Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the Internation ...

Core Viewpoint - Galapagos is re-evaluating its previously announced separation into two entities due to regulatory and market developments, focusing on maximizing resources for transformative business development transactions [3][4]. Group 1: Strategic Update - The company plans to explore all strategic alternatives for its existing businesses, including cell therapy, to enhance resource allocation for business development [3][4]. - The Board of Directors has appointed Mr. Henry Gosebruch as the new CEO, effective immediately, succeeding Dr. Paul Stoffels, who will retire in April 2025 [4][6]. - Mr. Jérôme Contamine has been appointed as the Chair of the Board of Directors, replacing Dr. Paul Stoffels [5][7]. Group 2: Leadership Transition - Mr. Gosebruch will lead the strategic evaluation process for Galapagos' current business while also focusing on building a pipeline of innovative medicines [4][6]. - Dr. Paul Stoffels will remain with the company in an advisory role, assisting in evaluating strategic options for the cell therapy pipeline, including the flagship program GLPG5101 [6][7]. Group 3: Future Directions - The company is currently assessing strategic options regarding its clinical programs and other assets, including potential mergers, divestitures, and out-licensing [7]. - The goal is to leverage the company's strong balance sheet and cash resources to pursue transformative business development opportunities [4][7].

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author previously wrote about Galapagos NV and its potential impact on the biotech landscape with its product GLPG5101 [2] - The article emphasizes the importance of thorough research and analysis in the biotech sector for investment decisions [2]

Core Insights - The first U.S. patient has been dosed in the ATALANTA-1 study of GLPG5101, targeting mantle cell lymphoma (MCL) as the lead indication, with pivotal development planned to start in 2026 and aiming for approval in 2028 [1][2][4] - Significant executive leadership changes are occurring, including the retirement of Dr. Paul Stoffels as CEO and the appointment of Henry Gosebruch as the Founding CEO of the new subsidiary SpinCo [1][12] - As of March 31, 2025, the company reported €3.3 billion in cash and financial investments, with a normalized annual cash burn guidance of €175 million to €225 million reaffirmed [1][20] Clinical Pipeline - The ATALANTA-1 Phase 1/2 study of GLPG5101 is focused on CD19 CAR-T therapy for eight hematological malignancies with high unmet needs, showing promising safety and efficacy in heavily pre-treated patients [3][4] - Enrollment is progressing across European clinical trial sites, with additional cohorts for Richter transformation and chronic lymphocytic leukemia planned for the near future [3][4] Financial Performance - Total net revenues for Q1 2025 were €75.0 million, a 20% increase from €62.4 million in Q1 2024, driven by a significant rise in supply revenues [10][13] - The company reported an operating loss of €158.7 million for Q1 2025, compared to a loss of €33.1 million in Q1 2024, largely due to costs associated with strategic reorganization [11][15] - Cash and cash equivalents totaled €3,297.3 million as of March 31, 2025, reflecting a net decrease of €20.5 million during the first quarter [18][19] Corporate Update - The planned separation of Galapagos into two independent entities, with SpinCo focusing on oncology, immunology, and virology, is expected to be completed by mid-2025 [7][20] - SpinCo will be funded with approximately €2.45 billion in cash and will pursue opportunities to build a pipeline of innovative medicines [7][20] Strategic Initiatives - The company is establishing operations in China to accelerate the development of its next-generation cell therapy pipeline [2][9] - Collaborations with Lonza and Thermo Fisher Scientific are being leveraged to scale up decentralized manufacturing capabilities [9][10]

Core Viewpoint - Galapagos NV is undergoing a planned separation into two independent entities, with Mr. Henry Gosebruch appointed as the founding CEO of the new subsidiary, SpinCo, which will focus on innovative medicines and is initially funded with approximately €2.45 billion in cash and cash equivalents [2][3]. Group 1: Leadership Changes - Dr. Paul Stoffels, the current CEO and Chair of the Board of Directors at Galapagos, plans to retire as CEO within the next 12 months but will remain as Chair, ensuring leadership continuity [1][3]. - The Board of Directors will search for a successor CEO for Galapagos, who will lead the company into its next phase of growth and innovation as a focused cell therapy company [3][4]. Group 2: SpinCo's Focus and Strategy - SpinCo will concentrate on building a pipeline of innovative medicines with demonstrated proof-of-concept, aiming to elevate the standard of care for patients through transformative transactions [2][3]. - The new entity will leverage a strong balance sheet and pursue opportunities that create significant value for shareholders [3][5]. Group 3: Background of Mr. Henry Gosebruch - Mr. Gosebruch has extensive experience in M&A, business development, and venture capital, previously serving as President and CEO at Neumora and Executive Vice President at AbbVie [6][7]. - At AbbVie, he was instrumental in completing over 100 business development transactions, including the acquisition of Allergan [7][8]. - His background includes over 20 years at J.P. Morgan, where he co-headed the North American M&A Group and worked on transactions exceeding $375 billion [8]. Group 4: Galapagos' Strategic Direction - Galapagos aims to transform into an R&D-driven biotech company with a focus on oncology, utilizing a decentralized manufacturing platform for cell therapies [4][9]. - The company is advancing its pipeline of potentially best-in-class assets, with ongoing Phase 2 clinical studies targeting aggressive hematological malignancies and solid tumors [4].

Core Points - Galapagos NV announced the departure of CFO and COO Thad Huston, effective August 1, 2025, for personal and professional reasons [1][2] - Huston joined Galapagos in 2023 to aid in its transformation into a cell therapy company, focusing on a decentralized cell therapy platform [2][3] - CEO Paul Stoffels expressed gratitude for Huston's contributions and emphasized the importance of a smooth transition before his departure [3] Company Overview - Galapagos NV is a global biotechnology company dedicated to transforming patient outcomes through innovative science [1] - The company is currently undergoing a transformation into a focused cell therapy business, leveraging its unique platform to deliver CAR-T therapy with a vein-to-vein time of seven days [3] Future Developments - Galapagos plans to announce Huston's successor in the coming months [2] - The company is also involved in a strategic separation into two public companies, which is expected to bring anticipated benefits and synergies [4]

Core Points - Galapagos NV has published its annual report for the financial year 2024 and announced its Annual Shareholders' Meeting (AGM) scheduled for April 29, 2025 [1][2] - The AGM agenda includes the appointment of Mr. Oleg Nodelman as Non-Executive Non-Independent Director and the confirmation of the statutory auditor for sustainability reporting [3] - The proposed separation of Galapagos into two publicly traded entities will not be discussed at the AGM, with an Extraordinary Shareholders' Meeting expected to be convened in mid-2025 regarding this matter [4] Company Overview - Galapagos is a biotechnology company operating in Europe and the U.S., focused on transforming patient outcomes through innovative science and technology [6] - The company aims to address high unmet medical needs and has developed a deep pipeline of best-in-class medicines, including a decentralized cell therapy manufacturing platform [6] - Galapagos is committed to anticipating future healthcare needs and ensuring that its innovations reach those who require them most [6]

Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The ...

Product Development Risks - The company is heavily dependent on the success of its clinical-stage product candidates, including oncology candidates GLPG5101 and GLPG5301, and immunology candidates GLPG3667[21] - Clinical development is lengthy and expensive, with uncertain outcomes, and earlier study results may not predict future trial results[22] - The regulatory approval processes in the US and Europe are lengthy and unpredictable, potentially affecting the commercial viability of products in development[24] - The company may not be successful in expanding its oncology portfolio and building a pipeline of product candidates due to limited resources[23] Financial Performance and Market Conditions - The company has limited historical profit from product sales, making it difficult to assess future prospects and financial results[30] - The market price of the American Depositary Shares (ADSs) could be subject to wide fluctuations[31] Competition and Market Dynamics - The company faces significant competition in drug discovery and development, which could reduce or eliminate commercial opportunities[28] - Legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for approved product candidates[28] Collaboration and Legal Risks - The company relies on a global R&D collaboration with Gilead, with no assurance that it will deliver expected benefits[29] - The company may face increased risks of securities class action litigation and shareholder activism[32]

Core Insights - Galapagos NV is a biotechnology company focused on transforming patient outcomes through innovative science and technology [3] - The company will present at two upcoming investor conferences in March 2025, showcasing its commitment to engaging with investors [1][2] Conference Details - The TD Cowen 45th Annual Healthcare Conference will take place on March 4, 2025, in Boston, MA, with a corporate presentation scheduled from 1:50 PM to 2:20 PM ET [1] - The Barclays 27th Annual Global Healthcare Conference is set for March 12, 2025, in Miami, FL, with a corporate presentation from 11:00 AM to 11:25 AM ET [2] Company Overview - Galapagos operates in Europe and the U.S., focusing on high unmet medical needs and developing a pipeline of best-in-class medicines [3] - The company utilizes a decentralized cell therapy manufacturing platform and aims to deliver innovative healthcare solutions [3] - Galapagos is dedicated to not only meeting current medical needs but also anticipating future healthcare challenges [3]